Reuters is reporting that experts are clashing over the safety of the cholesterol drug Vytorin as full results from a controversial study were presented at Europe’s biggest medical congress. Researchers involved in the so-called SEAS study – highlights of which were first released in July – said there was no credible evidence linking Vytorin to cancer and that the higher number of cases seen in the trial was simply a fluke.

My Take?

Here’s a note from my good friend, Thomas Dayspring, M.D., written for physicians (but, others are welcome to look on). Tom is one of the world’s most respected lipidologists (doctors who specializes in cholesterol problems):

Reuters and a number of other news agencies are reporting that the cholesterol fighter Vytorin s failed to meet the main goal of a study. They are also reporting that it is causing cancer. Are they telling you the truth?

My Take?